Danielle Elizabeth Dettling

Title: The Innovative Contributions of Danielle Elizabeth Dettling

Introduction

Danielle Elizabeth Dettling is a prominent inventor based in San Francisco, California. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies and chimeric antigen receptors. With a total of three patents to her name, her work is paving the way for advancements in cancer treatment.

Latest Patents

One of her latest patents focuses on chimeric antigen receptors targeting FLT3. This invention provides antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), along with engineered immune cells expressing such CARs, such as FLT3-specific CAR-T cells. The invention outlines methods for making these antibodies and CARs, as well as their use in treating conditions associated with malignant cells expressing FLT3, particularly cancer. Another significant patent involves antibodies specific for FLT3 and their therapeutic applications. This invention includes bispecific antibodies that bind to FLT3 and another antigen, such as CD3, and relates to methods for obtaining these antibodies and their use in treating FLT3-mediated pathologies, including Acute Myeloid Leukemia (AML).

Career Highlights

Danielle is currently employed at Pfizer Corporation, where she continues to innovate and contribute to the field of medical research. Her work is instrumental in developing new therapies that can potentially save lives and improve patient outcomes.

Collaborations

Some of her notable coworkers include Yik Andy Yeung and Cesar Adolfo Sommer, with whom she collaborates on various projects aimed at advancing cancer therapies.

Conclusion

Danielle Elizabeth Dettling's innovative work in biotechnology and her dedication to developing effective cancer treatments highlight her importance in the field. Her contributions are not only advancing scientific knowledge but also offering hope to patients battling cancer.